Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean F Bajorin

Showing results (131-140 of 169) with videos related to

Pageof 17
Sort By:
Nature Communications|April 12, 2022
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinomaJeppe Sejerø Holm, Samuel A Funt, Annie Borch, et al.
The Journal of Urology|February 1, 2023
Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial CarcinomaWesley Yip, Daniel D Sjoberg, Lucas M Nogueira, et al.
Cancer Discovery|June 18, 2014
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapyHikmat Al-Ahmadie, Gopa Iyer, Marcel Hohl, et al.
Science Translational Medicine|August 26, 2021
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockadeRonglai Shen, Michael A Postow, Matthew Adamow, et al.
JAMA Oncology|November 1, 2019
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder CancerAndrea B Apolo, Matthew I Milowsky, Lauren Kim, et al.
The Lancet. Oncology|May 13, 2024
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trialAndrea Necchi, Mathieu Roumiguié, Ashish M Kamat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World ExperienceBrendan J Guercio, Michal Sarfaty, Min Yuen Teo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2018
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial CarcinomaFrançois Audenet, Sumit Isharwal, Eugene K Cha, et al.
Cell Reports|December 21, 2022
Genomic heterogeneity as a barrier to precision oncology in urothelial cancerTimothy N Clinton, Ziyu Chen, Hannah Wise, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2007
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyJulie Gralow, Robert F Ozols, Dean F Bajorin, et al.
Pageof 17

Showing results (131-140 of 169) with videos related to

Sort By:
Pageof 17
Nature Communications|April 12, 2022
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinomaJeppe Sejerø Holm, Samuel A Funt, Annie Borch, et al.
The Journal of Urology|February 1, 2023
Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial CarcinomaWesley Yip, Daniel D Sjoberg, Lucas M Nogueira, et al.
Cancer Discovery|June 18, 2014
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapyHikmat Al-Ahmadie, Gopa Iyer, Marcel Hohl, et al.
Science Translational Medicine|August 26, 2021
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockadeRonglai Shen, Michael A Postow, Matthew Adamow, et al.
JAMA Oncology|November 1, 2019
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder CancerAndrea B Apolo, Matthew I Milowsky, Lauren Kim, et al.
The Lancet. Oncology|May 13, 2024
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trialAndrea Necchi, Mathieu Roumiguié, Ashish M Kamat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World ExperienceBrendan J Guercio, Michal Sarfaty, Min Yuen Teo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2018
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial CarcinomaFrançois Audenet, Sumit Isharwal, Eugene K Cha, et al.
Cell Reports|December 21, 2022
Genomic heterogeneity as a barrier to precision oncology in urothelial cancerTimothy N Clinton, Ziyu Chen, Hannah Wise, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2007
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyJulie Gralow, Robert F Ozols, Dean F Bajorin, et al.
Pageof 17